Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis

• Published in: Oncoimmunology Vol. 9; no. 1; p. 1832761
• Main Authors: Nugteren, Sandrine, Goos, Jeroen A.C.M., Delis-van Diemen, Pien M., Simons-Oosterhuis, Ytje, Lindenbergh-Kortleve, Dicky J., van Haaften, Daniëlle H., Sanders, Joyce, Meijer, Gerrit A., Fijneman, Remond J.A., Samsom, Janneke N.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2020; Taylor & Francis Group
• Subjects: colorectal cancer; Colorectal Neoplasms; Epithelial Cells; Humans; intestine; liver metastases; Liver Neoplasms; Medicin och hälsovetenskap; Original Research; Prognosis; Secretory Leukocyte Peptidase Inhibitor - genetics; SLPI; colorectal cancer; intestine; SLPI; liver metastases

Secretory leukocyte protease inhibitor (SLPI), a pleiotropic protein expressed by healthy intestinal epithelial cells, functions as an inhibitor of NF-κB and neutrophil proteases and exerts antimicrobial activity. We previously showed SLPI suppresses intestinal epithelial chemokine production in res...